vs
Side-by-side financial comparison of Indivior Pharmaceuticals, Inc. (INDV) and McGraw Hill, Inc. (MH). Click either name above to swap in a different company.
McGraw Hill, Inc. is the larger business by last-quarter revenue ($434.2M vs $357.0M, roughly 1.2× Indivior Pharmaceuticals, Inc.). Indivior Pharmaceuticals, Inc. runs the higher net margin — 28.9% vs -4.7%, a 33.5% gap on every dollar of revenue. McGraw Hill, Inc. produced more free cash flow last quarter ($285.4M vs $-245.0M).
Indivior is a global specialty pharmaceutical company dedicated to developing and commercializing evidence-based treatments for substance use disorders such as opioid use disorder and alcohol dependence, as well as related mental health conditions. Its primary operating markets are North America and Europe, with a portfolio of approved therapies targeting unmet medical needs for underserved patient groups.
McGraw Hill, Inc. is an American education science company that provides educational content, software, and services for students and educators across various levels—from K-12 to higher education and professional settings. They produce textbooks, digital learning tools, and adaptive technology to enhance learning experiences and outcomes. It is one of the "big three" educational publishers along with Houghton Mifflin Harcourt and Pearson Education. McGraw Hill also publishes reference and tra...
INDV vs MH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $357.0M | $434.2M |
| Net Profit | $103.0M | $-20.2M |
| Gross Margin | 82.1% | 85.3% |
| Operating Margin | 22.7% | 7.0% |
| Net Margin | 28.9% | -4.7% |
| Revenue YoY | — | -35.1% |
| Net Profit YoY | 390.5% | -119.2% |
| EPS (diluted) | $0.79 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $357.0M | $434.2M | ||
| Q3 25 | $314.0M | $669.2M | ||
| Q2 25 | $302.0M | $535.7M | ||
| Q1 25 | $266.0M | — | ||
| Q3 24 | $307.0M | — | ||
| Q2 24 | $299.0M | — |
| Q4 25 | $103.0M | $-20.2M | ||
| Q3 25 | $42.0M | $105.3M | ||
| Q2 25 | $18.0M | $502.0K | ||
| Q1 25 | $47.0M | — | ||
| Q3 24 | $22.0M | — | ||
| Q2 24 | $-97.0M | — |
| Q4 25 | 82.1% | 85.3% | ||
| Q3 25 | 73.2% | 79.2% | ||
| Q2 25 | 82.8% | 77.0% | ||
| Q1 25 | 83.1% | — | ||
| Q3 24 | 78.5% | — | ||
| Q2 24 | 73.6% | — |
| Q4 25 | 22.7% | 7.0% | ||
| Q3 25 | 13.7% | 23.4% | ||
| Q2 25 | 23.8% | 18.0% | ||
| Q1 25 | 24.8% | — | ||
| Q3 24 | 11.4% | — | ||
| Q2 24 | -39.5% | — |
| Q4 25 | 28.9% | -4.7% | ||
| Q3 25 | 13.4% | 15.7% | ||
| Q2 25 | 6.0% | 0.1% | ||
| Q1 25 | 17.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | -32.4% | — |
| Q4 25 | $0.79 | $-0.11 | ||
| Q3 25 | $0.33 | $0.57 | ||
| Q2 25 | $0.14 | $0.00 | ||
| Q1 25 | $0.38 | — | ||
| Q3 24 | $0.16 | — | ||
| Q2 24 | $-0.72 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.0M | $514.4M |
| Total DebtLower is stronger | — | $2.6B |
| Stockholders' EquityBook value | $-98.0M | $775.3M |
| Total Assets | $1.2B | $5.6B |
| Debt / EquityLower = less leverage | — | 3.36× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $195.0M | $514.4M | ||
| Q3 25 | $445.0M | $463.2M | ||
| Q2 25 | $510.0M | $247.3M | ||
| Q1 25 | $373.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | $2.6B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | — | $3.2B | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | $-98.0M | $775.3M | ||
| Q3 25 | $-207.0M | $794.6M | ||
| Q2 25 | $-257.0M | $283.3M | ||
| Q1 25 | $-285.0M | — | ||
| Q3 24 | $-310.0M | — | ||
| Q2 24 | $-281.0M | — |
| Q4 25 | $1.2B | $5.6B | ||
| Q3 25 | $1.4B | $6.0B | ||
| Q2 25 | $1.5B | $5.7B | ||
| Q1 25 | $1.4B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | 3.36× | ||
| Q3 25 | — | 3.52× | ||
| Q2 25 | — | 11.17× | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-221.0M | $309.0M |
| Free Cash FlowOCF − Capex | $-245.0M | $285.4M |
| FCF MarginFCF / Revenue | -68.6% | 65.7% |
| Capex IntensityCapex / Revenue | 6.7% | 5.4% |
| Cash ConversionOCF / Net Profit | -2.15× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-221.0M | $309.0M | ||
| Q3 25 | $-39.0M | $265.0M | ||
| Q2 25 | $158.0M | $-96.7M | ||
| Q1 25 | $75.0M | — | ||
| Q3 24 | $2.0M | — | ||
| Q2 24 | $88.0M | — |
| Q4 25 | $-245.0M | $285.4M | ||
| Q3 25 | $-59.0M | $243.8M | ||
| Q2 25 | $141.0M | $-112.9M | ||
| Q1 25 | $70.0M | — | ||
| Q3 24 | $-5.0M | — | ||
| Q2 24 | $84.0M | — |
| Q4 25 | -68.6% | 65.7% | ||
| Q3 25 | -18.8% | 36.4% | ||
| Q2 25 | 46.7% | -21.1% | ||
| Q1 25 | 26.3% | — | ||
| Q3 24 | -1.6% | — | ||
| Q2 24 | 28.1% | — |
| Q4 25 | 6.7% | 5.4% | ||
| Q3 25 | 6.4% | 3.2% | ||
| Q2 25 | 5.6% | 3.0% | ||
| Q1 25 | 1.9% | — | ||
| Q3 24 | 2.3% | — | ||
| Q2 24 | 1.3% | — |
| Q4 25 | -2.15× | — | ||
| Q3 25 | -0.93× | 2.52× | ||
| Q2 25 | 8.78× | -192.53× | ||
| Q1 25 | 1.60× | — | ||
| Q3 24 | 0.09× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INDV
| Sublocade | $233.0M | 65% |
| Sublingual And Other | $69.0M | 19% |
| Other | $49.0M | 14% |
| Perseris | $6.0M | 2% |
MH
| Higher Education | $225.4M | 52% |
| Digital | $103.5M | 24% |
| Other | $44.4M | 10% |
| Global Professional | $36.2M | 8% |
| $24.7M | 6% |
